Research Expands Knowledge of Relationship Between BRCA Mutations, Cancer

Countless studies have proven a relationship between BRCA mutations and breast and ovarian cancers. Unfortunately, major gaps still exist related to the mechanisms that modify the risk of cancer among patients with BRCA1/2 mutations.
 
The authors of new research published by Molecular Cell discovered 3 genes in BRCA1/2- deficient cells that may add to the risk of cancer. Specifically, these genes fuel genome instability during DNA repair, which can lead to lesions and tumors.
 
“Our studies raise the possibility that inhibition of these genes could reduce the occurrence of breast and ovarian cancer in BRCA1/2 mutation carriers,” said study leader Alberto Ciccia, PhD. “We are currently conducting experiments to test this hypothesis.”
 
Normal BRCA1/2 genes are tumor suppressors and make sure that breast and ovarian cells grow normally. If the genes become mutated, cells can rapidly divide unchecked, which is a common precursor to cancer.
 
During cell replication, DNA double helixes unwind and separate. Each half of the DNA acts as a template for the creation of a new strand, according to the authors.
 
When the DNA strand separates, the halves form a replication fork. If the replicating DNA becomes stressed, BRCA genes prevent the forks from being degraded, thereby avoiding genomic instability, according to the study.
 
The authors discovered that the SMARCAL1, ZRANB3, and HLTF genes cause fork degradation in cells with mutated BRCA genes.
 
Deficiency in these 3 genes was observed to restore fork integrity and lowered genome instability in cells with mutated BRCA1/2, according to the study. This action suppresses DNA lesions that may increase the risk of cancer.
 
The authors also found that inhibiting SMARCAL1 in BRCA1-deficient breast cancer cells resulted in chemotherapy resistance, according to the study. Identifying a defense mechanism in breast cancer cells could inform the development of novel therapies for chemotherapy-resistant disease, the authors concluded. 


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Research may lead to potential new targets for preventing cancer in humans.
Study suggests future interventions targeting improvements in cancer screenings may need to focus on the time of day when a patient visits a doctor.
Top news of the week from Specialty Pharmacy Times.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$